Antimicrobials
Ceftriaxone

Ceftriaxone

High
N/A
$

General Information

  • EMPIRIC therapy of severely ill patients with suspected Gram-negative infection
  • Documented Gram-negative infection resistant to 1st and 2nd generation cephalosporins
  • Meningitis, brain abscess
  • Spontaneous bacterial peritonitis, community-acquired secondary peritonitis (or hospital acquired with no previous antimicrobial therapy), or intra-abdominal abscess
  • Salmonella
  • Community acquired pneumonia
  • Gonorrhea
  • Pelvic Inflammatory Disease, Epididymitis
  • Some endocarditis infections
  • Synergy in some Enterococci endocarditis infections, particularly if gentamicin is contraindicated
  • Complicated Lyme infections
  • Does not cover Listeria, Pseudomonas, ESBLs or AmpC producing Enterobacteriaceae
  • Avoid in patients with biliary sludging or cholestatic hepatitis (see Cefotaxime)
  • Avoid for serious Citrobacter or Enterobacter infections, even if reported as susceptible

Potential link to seizure risk.

  • Allergy/rash (immediate or delayed)
  • Cytopenias
  • Eosinophilia
  • Hepatic & renal laboratory abnormalities
  • Pseudocholelithiasis (more likely if on TPN and using ≥ 2 g/day)
  • Drug induced immune thrombocytopenia
  • Potential link to seizure risk (1%)
  • May cause prolonged QTc when combined with lansoprazole. Caution advised when QTc is > 500 milliseconds

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic